Eyenovia Inc (EYEN) Misses Q4 EPS by 17c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/28/2026
- First Financial to acquire Hickory Point Bank in $111.3M deal
- Affirm Holdings (AFRM) Tops Q4 EPS by $3.77, Beats on Revenue
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- Ovintiv adds 41,000 acres in Permian and Montney deals
- Russia says it could strike UK military targets in response to Kyiv's use of British missiles
Eyenovia Reports Fourth Quarter and Full Year 2018 Financial Results
March 27, 2019 6:30 AM EDTNEW YORK, March 27, 2019 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, today announced its financial results for the fourth quarter and full year ended December 31, 2018.
Q4 2018 and Recent Business Highlights
Reported positive results in the MicroStat Phase III MIST-1 and MIST-2 registration studies for mydriasis;U.S. Food and Drug Administration (FDA) accepted investigational new drug... More